Artrya

Artrya is a medical technology company based in Perth, Australia that has developed an AI-powered software solution called Artrya Salix to assist physicians in diagnosing coronary artery disease. Salix Coronary Anatomy (SCA) is the company's flagship product, which uses deep learning algorithms to analyze cardiac CT scans and identify the presence and extent of atherosclerotic plaque, including high-risk vulnerable plaque components that are prone to rupturing and causing heart attacks.

The AI-based technology provides a comprehensive 3D visualization of the heart within 10-15 minutes, highlighting coronary artery disease biomarkers such as stenosis, calcium scores, and total plaque burden. This rapid diagnosis aids clinicians in developing personalized treatment plans for patients at risk of acute coronary events. Artrya's solution aims to revolutionize the management of coronary artery disease, a condition that costs the US healthcare system over USD 200 billion annually.

In March 2022, Artrya established its US subsidiary, Artrya US, Inc., headquartered in Los Angeles, California, to spearhead its entry into the significant American market. The company's expansion followed the appointment of Dr. Jacque J. Sokolov as the Chair of Artrya's Clinical Advisory Board in January 2022. As of December 2023, Artrya Salix Coronary Anatomy has received regulatory approvals in Australia, New Zealand, the UK, and the European Union.